ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 928,91
-0,70%
Dow Jones
37 903,29
0,00%
DAX
17 938,71
0,09%
Brent Oil
84,23
0,83%
Bitcoin
58 973,42
1,26%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) Actualités

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IONS
DateHeureSourceTitreSymboleSociété
25/04/202413h00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
23/04/202413h05PR Newswire (US)Ionis to hold first quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
07/04/202415h48PR Newswire (US)Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
01/04/202413h05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
28/03/202412h05PR Newswire (US)Ionis to hold olezarsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
25/03/202413h18PR Newswire (US)Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingNASDAQ:IONSIonis Pharmaceuticals Inc
13/03/202412h00PR Newswire (US)Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHNASDAQ:IONSIonis Pharmaceuticals Inc
06/03/202413h30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202401h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202415h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202415h05PR Newswire (US)Ionis announces new chief global product strategy officer to lead next phase of commercial growthNASDAQ:IONSIonis Pharmaceuticals Inc
21/02/202413h00PR Newswire (US)Ionis reports fourth quarter and full year 2023 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
20/02/202416h39Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
16/02/202422h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
15/02/202413h00PR Newswire (US)Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
14/02/202416h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IONSIonis Pharmaceuticals Inc
13/02/202412h09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
08/02/202413h00PR Newswire (US)Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathyNASDAQ:IONSIonis Pharmaceuticals Inc
07/02/202413h05PR Newswire (US)Ionis to hold fourth quarter and full year 2023 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
22/01/202413h00PR Newswire (US)Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
08/01/202413h03PR Newswire (US)Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseasesNASDAQ:IONSIonis Pharmaceuticals Inc
22/12/202301h38Dow Jones NewsIonis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare Genetic Disease TreatmentNASDAQ:IONSIonis Pharmaceuticals Inc
22/12/202300h55PR Newswire (US)WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosisNASDAQ:IONSIonis Pharmaceuticals Inc
20/12/202313h05PR Newswire (US)Ionis to present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IONSIonis Pharmaceuticals Inc
18/12/202322h56Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
18/12/202322h01PR Newswire (US)Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
14/12/202322h05PR Newswire (US)Ionis announces the appointment of Michael Yang to Board of DirectorsNASDAQ:IONSIonis Pharmaceuticals Inc
24/11/202319h31Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:IONSIonis Pharmaceuticals Inc
16/11/202314h00GlobeNewswire Inc.Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesNASDAQ:IONSIonis Pharmaceuticals Inc
11/11/202317h30PR Newswire (US)Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS

Dernières Valeurs Consultées

EU
PX4
SBF 120
EU
RI
Pernod Ricard
EU
VIV
Vivendi
EU
BEL20
Bel 20
EU
CAP
Capgemini
EU
LR
Legrand
EU
RNO
Renault
FTSE
UKX
FTSE 100
NYSE
DIS
Walt Disney
COIN
BTCUSD
Bitcoin
EU
ACA
Credit Agricole
NYSE
MCD
McDonalds
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés